Health authorities and medical experts are raising alarm over the growing circulation of illegally compounded tirzepatide being sold through online and unregulated channels, warning that these products may pose serious risks to patients.
“Zuellig Pharma is aware of the growing concerns around the sale of illegally compounded Tirzepatide through unregulated and unauthorized channels,” the company said, as questionable versions of the drug continue to surface on social media and other digital platforms.
Tirzepatide is a prescription-only treatment for obesity and type 2 diabetes that was recently approved by the Philippine Food and Drug Administration.
Developed by Eli Lilly and Company and marketed locally under the brand name Mounjaro, it is distributed in the Philippines exclusively by Zuellig Pharma.
Despite its regulated availability, unauthorized and compounded versions have begun appearing online, prompting concern from both industry and the medical community.
Several professional groups, including the Philippine College of Physicians and the Institute for Studies on Diabetes Foundation Inc., have issued public health advisories warning of the “unforeseen health risks” linked to these products. Because compounded tirzepatide bypasses regulatory review, experts caution that patients cannot be assured of its safety, quality, or effectiveness.
Among the risks flagged are improper dosing, which “may lead to severe adverse effects” without regulatory oversight, as well as the presence of impurities.
“Testing by Lilly has identified unknown impurities in compounded products, particularly those mixed with substances such as vitamin B12, which may trigger harmful chemical reactions,” the statement noted.
These products have also not undergone the clinical trials and evaluations required by regulators, increasing the likelihood of unpredictable outcomes for patients.
Amid these concerns, Zuellig Pharma is urging the public to avoid purchasing prescription medicines from unverified sources.
“Zuellig Pharma strongly urges consumers not to purchase Tirzepatide or similar prescription medicines from social media platforms, unauthorized online sellers, or other unregulated sources,” the company said, adding that patients unsure about their medication should consult their doctor or pharmacist immediately.
Healthcare professionals are likewise being reminded to prescribe only FDA-approved treatments and to educate patients about the dangers of unregulated drugs.
The company, alongside the Philippine College of Physicians and the Institute for Studies on Diabetes Foundation Inc., reaffirmed its commitment to patient safety through access to evidence-based therapies and continued collaboration with regulators.
